Kevin W Hunt

USPTO Granted Patents = 22 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 12)

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Longmont, CO (US) (2007 - 2020)
Boulder, CO (US) (2013 - 2024)

Company Filing History:

Edgewise Therapeutics, Inc.

Edgewise Therapecutics, Inc.

patents

5. 1 out of 1,149

Vertex Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448369 - Quinolinone amide compounds and uses thereof (2025-10-21),

2. 12415794 - Pyridazinone compounds and uses thereof (2025-09-16),

3. 12240833 - Pyridazinone compounds and uses thereof (2025-03-04),

4. 12240831 - Pyridazinone compounds and uses thereof (2025-03-04),

5. 12012395 - Pyridazinone compounds and uses thereof (2024-06-18),

6. 11390606 - Pyridazinone compounds and uses thereof (2022-07-19),

7. 11236065 - Pyridazinone compounds and uses thereof (2022-02-01),

8. 11091464 - Pyridazinone compounds and uses thereof (2021-08-17),

9. 10766881 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2020-09-08),

10. 10208024 - 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases (2019-02-19),

11. 10154995 - Serine/threonine kinase inhibitors (2018-12-18),

12. 9763942 - Serine/threonine kinase inhibitors (2017-09-19),

13. 9670208 - Serine/threonine kinase inhibitors (2017-06-06),

14. 9556139 - 6-substituted phenoxychroman carboxylic acid derivatives (2017-01-31),

15. 9096567 - 6-substituted phenoxychroman carboxylic acid derivatives (2015-08-04),

Title: Kevin W. Hunt: Innovator in Neuromuscular Disease Treatment

Introduction: Kevin W. Hunt, based in Longmont, Colorado, is an accomplished inventor with a remarkable portfolio of 21 patents. His contributions primarily lie in the field of pharmacology, particularly aimed at addressing neuromuscular diseases.

Latest Patents: Among Hunt's recent inventions is a series of patents concerning substituted pyridazinone compounds. These innovative compounds and their associated pharmaceutical compositions have been specifically designed for the treatment of neuromuscular diseases like Duchenne Muscular Dystrophy (DMD). The disclosed compounds not only aim to treat DMD but also play a crucial role in modulating inflammatory inhibitors such as IL-1, IL-6, and TNF-α.

Career Highlights: Throughout his career, Kevin W. Hunt has made significant advancements in his field while working with notable companies, including Array Biopharma Inc. and Edgewise Therapeutics, Inc. His role in these organizations has allowed him to focus on innovative solutions for complex medical conditions.

Collaborations: Kevin has collaborated with esteemed colleagues, including Adam Wade Cook and Laurence Edward Burgess, emphasizing the importance of teamwork in driving forward significant pharmaceutical innovations.

Conclusion: Kevin W. Hunt's dedication to innovating treatment methods for neuromuscular diseases makes him a prominent figure in the field. His extensive patent portfolio reflects his commitment to improving patient outcomes through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.